Tourette Syndrome Market Report 2026

The tourette syndrome market size has grown rapidly in recent years. It will grow from $2.15 billion in 2025 to $2.38 billion in 2026 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to improved clinical understanding of tic disorders, increased diagnosis rates in pediatric populations, expansion of neurological research funding, availability of standardized diagnostic criteria, growth in behavioral therapy adoption.

The tourette syndrome market size is expected to see rapid growth in the next few years. It will grow to $3.48 billion in 2030 at a compound annual growth rate (CAGR) of 10%. The growth in the forecast period can be attributed to increasing investment in precision neurology research, rising development of personalized treatment pathways, expansion of digital therapeutic tools, growing focus on non-invasive neuromodulation approaches, increasing global awareness initiatives. Major trends in the forecast period include increasing focus on early and accurate diagnosis, growing adoption of behavioral and digital therapies, rising research on genetic and neurobiological factors, expansion of multidisciplinary care approaches, improved awareness and screening programs.

The increasing government initiatives for neurological disorders are expected to drive the growth of the tourette syndrome market. Government initiatives are programs, policies, or actions implemented by authorities to address public needs, promote development, or improve societal well-being. Such initiatives for neurological disorders support advancements in tourette syndrome by increasing funding for research and treatment programs, leading to improved diagnostic tools, better therapeutic options, and greater public awareness, ultimately enhancing patient care and support. For example, in February 2025, according to a report by the Department of Health and Social Care, a UK-based ministerial department, the Medical Research Council (MRC) established the first two MRC Centres of Research Excellence (CoRE) in December 2024, each dedicated to gene therapy research and valued at up to $65 million (£50 million) over 14 years. The MRC CoRE in therapeutic genomics aims to drive transformative progress in rare genetic disorders by developing scalable processes to adapt successful genetic therapies for new conditions, facilitating the creation of personalized treatments. Therefore, increasing government initiatives for neurological disorders are supporting the growth of the tourette syndrome market.

Leading companies in the tourette syndrome market are focusing on incorporating dopamine 1 (D1) receptor antagonists to gain a competitive advantage. D1 receptor antagonists are drugs that block dopamine D1 receptors in the brain, reducing dopamine activity to help manage neurological or psychiatric conditions. For example, in March 2023, Emalex Biosciences, a US-based biopharmaceutical company, launched a Phase 3 trial of ecopipam, a first-in-class small molecule drug that selectively blocks D1 receptors rather than the D2 receptors targeted by existing antipsychotics. Ecopipam showed significantly lower relapse rates in pediatric patients - 41.9% relapse versus 68.1% with placebo (hazard ratio 0.5, p = 0.0084) - and maintained reductions in vocal and motor tics with generally good tolerability (common side effects included somnolence, insomnia, anxiety, fatigue, and headache). This move toward a more targeted pharmacological mechanism expands therapeutic options and could drive adoption, though long-term real-world safety and access remain to be evaluated.

In February 2025, Relmada Therapeutics Inc., a US-based biotechnology company, acquired Sepranolone, a Phase 2b-ready neurosteroid, from Asarina Pharma AB for an undisclosed amount. The acquisition aligns with Relmada’s mission to address unmet needs in the treatment of central nervous system (CNS) disorders. Sepranolone demonstrated promising results in Phase 2a trials, with significant reductions in tics, improvements in quality of life, and strong safety data. Asarina Pharma AB is a Sweden-based provider of tourette syndrome treatments.

Major companies operating in the tourette syndrome market are Teva Pharmaceutical Industries Ltd, Neurocrine Biosciences Inc, Jazz Pharmaceuticals plc, Eisai Co Ltd, Kyowa Kirin Co Ltd, AbbVie Inc, SciSparc Ltd, Emalex Biosciences Inc, Pfizer Inc, H Lundbeck AS, Otsuka Pharmaceutical Co Ltd, Sage Therapeutics Inc, Axsome Therapeutics Inc, Johnson and Johnson Services Inc, Horizon Therapeutics Plc, Medtronic plc, Noema Pharma Inc, Asarina Pharma AB, EuMentis Therapeutics Inc, Synendos Therapeutics Inc, Catalyst Pharmaceuticals Inc.

North America was the largest region in the tourette syndrome market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tourette syndrome market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tourette syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are indirectly impacting the tourette syndrome market by increasing costs of imported diagnostic equipment, neuromodulation devices, digital therapy platforms, and pharmaceutical research inputs used in diagnosis and symptom management. Healthcare systems in North America and Europe are most affected due to dependence on imported medical technologies, while emerging markets face higher costs for advanced diagnostic tools. These tariffs contribute to increased treatment and research expenses, potentially slowing adoption in cost-sensitive regions. However, they are also encouraging domestic medical device production, local clinical research investments, and regional development of cost-effective diagnostic and therapeutic solutions.

The tourette syndrome market research report is one of a series of new reports that provides tourette syndrome market statistics, including tourette syndrome industry global market size, regional shares, competitors with a tourette syndrome market share, detailed tourette syndrome market segments, market trends and opportunities, and any further data you may need to thrive in the tourette syndrome industry. This tourette syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Tourette syndrome (TS) is a neurological condition characterized by involuntary, repetitive movements and vocalizations called tics. It typically begins in childhood and can range in severity. Both genetic and environmental factors contribute to TS, and symptoms often intensify during periods of stress or excitement. Treatments, including behavioral therapy and medications, can help manage symptoms and reduce the frequency of tics.

The primary types of Tourette syndrome are motor tics and vocal tics. Motor tics involve sudden, involuntary body movements, such as blinking, head jerking, or shoulder shrugging. Diagnosis can be conducted through blood tests, imaging, and other methods, while treatment options include medications, behavioral therapy, neuromodulation therapies, complementary and alternative medicine, and more. The condition can be classified as mild, moderate, or severe and is relevant to individuals with Tourette syndrome, healthcare professionals, educational institutions, non-profit organizations, and research institutions.

The tourette syndrome market consists of sales of sensory stimulation devices, neurofeedback devices, speech and communication aids, mental health support apps. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.